Understanding the market for pharmacogenomic testing

**药物基因组学的实施是自为确定药物的安全性和有效性而开展的对照试验以来，最具创新性和激动人心的处方药方法**。通过分析患者的DNA，医生现在可以做出量身定做的处方选择，最大限度地增加首次以最有效的剂量选择正确药物的机会。这是药物基因组学(或称PGx)。**PGx的主要好处预计是：**1)缩短药物产生治疗效果的时间，2)减少多药联用，3)避免药物不良反应，目前NHS每年花费约5亿GB来管理和治疗因此而住院的人。当公共卫生系统正在努力解决围绕PGx广泛实施的问题时，预计需要几年的时间才能解决，我们已经有了一个解决方案，使私人能够要求自己的测试。然而，由于这是一项新技术，相对较少的人知道，从患者的角度来看，对实施的障碍知之甚少，也不知道如何支持他们的全科医生或处方药剂师使用我们提供的信息。虽然许多药物已经带有可供医生遵循的基因指导，但它们通常无法获得患者的基因信息，因此，我们无法在开处方时考虑这一重要因素。我们希望加快PGx的私人实施，以便能够更快、更顺利地及时采用该技术，并建立对该技术的信任。**我们的建议是开展结构化的市场研究，重点关注以下群体：**1)私人自费患者2)全科医生3)药剂师**我们将对目标市场进行定量和定性分析，以了解：**1)人们对PGx的看法是什么2)使用PGx的主要障碍/担忧是什么(以及我们如何建立信任技术)3)患者最有可能如何访问PGx(通过医生/HCP或直接)4)产品定价有多敏感以及什么水平最大限度地吸收**该项目将分为3部分：**1)大规模定量研究2)涉及一小群患者的较小规模定性分析3)涉及一小群医生的较小规模定性分析，药剂师和HCP这项研究将使我们能够通过更好的患者目标定位来加快PGx的实施。

**The implementation of pharmacogenomics is the most innovative and exciting approach to prescription medicine since controlled trials were developed to determine a drug's safety and efficacy**. By profiling a patient's DNA, it is now possible for doctors to make tailored prescription choices, maximising the chances of choosing the right medicine, first time, and at the most effective dose. This is pharmacogenomics (or PGx).**The main benefits of PGx are expected to be:**1) reduced time to therapeutic benefit from a drug,2) reduction in polypharmacy, and3) the avoidance of adverse drug reactions, which currently cost the NHS an estimated £500m a year to manage and treat those hospitalised as a result.While public health systems are grappling with the issues around widespread implementation of PGx, which are expected to take several years to resolve, we have a solution which is already on the market enabling private individuals to order their own test. However, as this is a new technology which relatively few people are yet aware of, little is known about the barriers to implementation from a patient's perspective or how their GP or prescribing pharmacist will need to be supported to use the information we provide. Whilst many drugs already carry genetic guidance for doctors to follow, they do not routinely have access to the patient's genetic information, so are unable to consider this important factor when prescribing.We want to speed up the private implementation of PGx to enable a faster and smoother path to public health adoption in time and build trust in the technology.**Our proposal is to carry out structured market research focusing on the following groups:**1) Private self-paying patients2) General practitioners3) Pharmacists**We will carry out quantitive and qualitative analysis of the target market to understand:**1) what people's perceptions of PGx are2) what the main barriers/concerns are for the use of PGx (and how do we build trust in the technology)3) how patients are most likely to access PGx (via doctor/HCP or direct)4) how sensitive product pricing is and what level maximises uptake**The project will be divided into 3 parts:**1) large scale quantitive study2) smaller scale qualitative analysis involving a small group of patients3) smaller scale qualitative analysis involving a small group of doctors, pharmacists and HCPsThis study will enable us to speed up implementation of PGx through better patient targeting.